C-JRLQCSF delivery, precision dosing, neurotechnology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Explore use of EnClear's CSF delivery and precision dosing approach in autoimmune and epilepsy indications including autoimmune epilepsy and lupus.
Potential application of the EnTrega CSF Platform for CNS therapeutic delivery in listed autoimmune and epilepsy indications.
Company pipeline lists Autoimmune Epilepsy and Lupus as programs or target indications for partnership.
Treat leptomeningeal carcinomatosis by improving CNS delivery and dosing of therapeutics for neuro-oncology patients.
Use the EnTrega CSF Platform for controlled CSF circulation, drug delivery, and monitoring in CNS malignancy settings.
Lead neuro-oncology program listed on the company pipeline; first-in-human EnTrega study planned to open in Q2 2026.
Preclinical EnTrega methotrexate delivery in sheep produced controllable CSF flow and therapeutic-level brain parenchymal drug penetration.
Enable controlled, continuous, personalized cerebrospinal fluid delivery and monitoring to optimize CNS therapeutic dosing while reducing peripheral toxicity and severe side effects.
Device-based CSF access, controlled extracorporeal CSF circulation, precision dosing, CSF sampling, and sensor-array monitoring of intracranial pressure, respiration, and heart rate.
Large-animal EnTrega studies demonstrated controlled CSF circulation and brain parenchymal methotrexate distribution; a first-in-human study was planned to open in Q2 2026.
In healthy sheep, dye studies confirmed controllable CSF flow; sensor arrays kept monitored parameters within safe limits; methotrexate reached bilateral brain distribution and therapeutic-level parenchymal penetration including deep structures.
Evaluate whether dual-location CSF pressure sensing can support safer, more personalized intra-CSF drug administration for CNS metastases and leptomeningeal carcinomatosis patients.
Non-human primate study using EnClear device intracranial and intralumbar CSF access with single-use sensing arrays to measure intracranial pressure before, during, and after intracerebroventricular infusion.
Non-human primate pressure-response study reported variable subject-specific intracranial elastance and concordance between lumbar and cranial pressure waveforms.
Ventricular and lumbar ICP waveforms were strongly correlated, with average correlation coefficient of 0.88; identical infusion volumes produced variable maximum pressures ranging from 20 mmHg to 40 mmHg.
Compare safety, clinical efficacy, pharmacokinetics, and drug distribution across intra-CSF delivery approaches to inform improved CNS drug-delivery tools.
Retrospective literature review of intracerebroventricular, lumbar intrathecal, and intra-cisterna magna drug-delivery studies in clinical literature.
2025 Cancers review and 2023 Neuro-Oncology abstract summarized safety and distribution profiles for intra-CSF delivery methods.
ICV and LIT safety profiles were reported as acceptable with mostly mild-to-moderate procedure-associated adverse events; ICV achieved therapeutic goals more consistently than other intra-CSF methods.
Explore use of EnClear's CSF delivery and precision dosing approach in lysosomal storage disease indications including Gaucher, Hunters, and Tay-Sachs.
Potential application of the EnTrega CSF Platform for CNS therapeutic delivery in listed lysosomal storage disease indications.
Company pipeline lists Gaucher, Hunters, and Tay-Sachs as programs or target indications for partnership.
Explore use of EnClear's CSF delivery and precision dosing approach in neurodegenerative indications including Huntington's disease, ALS, and FTD.
Potential application of the EnTrega CSF Platform for CNS therapeutic delivery in listed neurodegenerative indications.
Company pipeline lists Huntington's, ALS, and FTD as programs or target indications for partnership beyond the lead neuro-oncology program.